Antibodies and Reagents
for Cancer Research
The Vector Laboratories portfolio now includes a synergistic collection of antibody-centric brands — Absolute Antibody, LSBio, Everest Biotech, Exalpha, Nordic-MUbio, and Kerafast.
Cancer is the leading cause of death worldwide, and cancer research is crucial for better targeted therapies, improved diagnostic methods, and deeper understanding of the pathways involved in tumor pathogenesis. To empower cancer researchers, Vector Laboratories has curated antibodies targeting key antigens and reagents enabling streamlined workflows for cancer research.
Cancer Research Application Workflows
Successful workflows in cancer research begin with high-quality reagents and antibodies. With nearly 50 years of experience producing and providing scientists with the best tools for the job, the Vector catalog offers highly cited antibodies and reliable reagents designed to streamline workflows. Learn more about our end-to-end application workflow solutions for immunohistochemistry (IHC) and immunofluorescence (IF).
Cancer Research Solutions
Vector Laboratories is committed to providing high-quality research antibodies and reagents for cancer research that support a variety of applications and provide reliable performance. The following Vector products empower researchers to explore cancer therapeutic development, diagnostics, and research.
Primary Antibodies for Cancer Research
The specificity and sensitivity of antibodies can unlock discoveries in cancer research, but not all antibodies are created equal. We produce best-in-class antibodies against a variety of targets relevant to cancer research.
Recombinant Antibodies
Our Absolute Antibody brand specializes in recombinant antibodies, which ensure batch-to-batch reproducibility and enable new antibody engineering opportunities.
Our immunotherapy antibodies target clinically relevant antigens and include VivopureX™ mouse-anti-mouse antibodies with tailored effector function for therapeutic modulation and reduced immunogenicity in vivo.
Research-grade biosimilars are identical to therapeutic-grade biologics at a fraction of the cost and are available in different constant domains.
Additionally, we offer tumor marker antibodies built to bind specifically to tumor associated antigens.
IHC-Validated Antibodies
Our LSBio brand specializes in IHC validation, offering more than 15,000 antibodies validated for immunohistochemistry with a focus on cancer biomarkers.
IHC-Plus™ antibodies have been rigorously tested to deliver optimal performance in immunohistochemistry (IHC) studies on formalin-fixed paraffin-embedded (FFPE) human tissues.
PathPlus™ antibodies represent the highest quality reagents available for research pathology applications, shown to be the best performing reagents for immunohistochemical detection of high-value cancer targets.
Goat Polyclonal Antibodies
Our Everest brand specializes in anti-peptide and antigen affinity purified goat polyclonal antibodies, especially useful in applications that require high affinity antibodies at cost-effective prices.
The catalog contains thousands of goat antibodies against a broad range of human, mouse, and rat proteins of biomedical interest, like IGF1, FOXP3/SCURFIN, and CEP290. Many of Everest’s antibodies include validation data in ELISA and western blot (WB) applications.
Featured Primary Antibodies
These highly-cited antibodies from the Vector portfolio target antigens of interest in cancer research.
Anti-Laminin Rat Antibody (MUB1100P)
Immunofluorescence staining of frozen sections from human colon (methanol fixed) using MUB1100P, showing the localization of laminin, a protein that plays a role in tumorigenesis and metastasis in a variety of cancer types.
Featured Cancer Research Areas
Our high-quality antibodies and reagents support cancer research across multiple applications, enabling the study of key biomarkers and pathways in breast, colorectal, lung, and prostate cancer. Explore how our products advance research in these featured cancer types.
Breast Cancer
Labeling specific markers is crucial for breast cancer research, from tumor characterization to therapy selection and mechanistic studies. Standard markers like HER2, ER, and PR guide treatment, while Ki-67, TP53, and p63 assess proliferation and invasion. Antibody-based tools also support genetic research on BRCA mutations and predictors like SIAH2 and EGFR. Our reagents enable precise biomarker analysis across various applications.
Colorectal Cancer
Colorectal carcinoma (CRC) affects 4% of the population, requiring reliable reagents for diagnostics and therapy development. Antibodies aid in biomarker identification, including CDX2 and Villin, oncogenic mutations in chromosomal instability, and targets for therapies like EGFR and VEGF inhibitors. Our products , advancing CRC research and treatment strategies.
Lung Cancer
Lung cancer remains a leading cause of cancer deaths, with accurate biomarker detection critical for classification and treatment. Tissue-specific markers like TTF-1 and p63 help subtype tumors, while EGFR, ALK, and PD-L1 guide targeted therapies. Frequent mutations in KRAS, BRAF, and TP53 further shape lung cancer progression. Our antibodies support diagnostics, biomarker research, and therapeutic development.
Prostate Cancer
Prostate cancer is the most common non-skin cancer in men, requiring precise biomarker detection for diagnosis and treatment. Antibodies help identify key markers such as PSA, Prostein, NKX3-1, p63, and AMACR while enabling research into AR, WNT, and PI3K pathway alterations. Our reagents support diverse applications, advancing diagnostics and therapeutic development for prostate cancer.
Technical and Educational Cancer Research Resources
For more information on how Vector’s portfolio of products supports cancer research, explore the following resources.
Therapeutic Antibody Mechanisms of Action
Learn more about how antibody therapeutics work for cancer and other diseases, including how antibody format affects treatment efficacy.
IHC-Validated Cancer Research Antibodies from LSBio
These pages provide further information on clinically relevant antibody targets for each cancer type, as well as offering IHC-validated antibody options for each.
IHC-Validated Cancer Research Antibodies from LSBio
These pages provide further information on clinically relevant antibody targets for each cancer type, as well as offering IHC-validated antibody options for each.
Anti-Tumor Efficacy of Syngeneic Engineered Anti-PD-1 vs. Original Antibody
This research poster demonstrates that a recombinant, species-switched version of an anti-PD-1 antibody shows greater therapeutic efficacy in vivo than the original version.
